BioSpace News Archive

End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Executed clinical collaboration agreement in oncology with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) Senior executives hired for key positions Cash, cash equivalents and financial assets were €115.8 million as o

- Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids -

The employee analytics, engagement, monitoring and testing solution is designed to protect workers and foster confidence as employers lay out plans for workforce re-entry.

Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development

Incyte announced that it will present at the 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 3:05 p.m. ET..

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced that it will report its first quarter 2020 financial and operating results on Thursday, May 7, 2020, following the close of the U.S. financial markets.

Cadent Therapeutics , a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, today announced today that it has closed the $15 million final equity tranche of its previously announced $40 million Series B financing. The Company plans to allocate all proceeds to continue the development for its lead cognitive disor

Taysha Gene Therapies today announced it has launched with a mission to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS) by advancing its pipeline of 15 AAV (adeno-associated virus) gene therapy programs, with options to an additional four programs.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced the appointment of Satnam Alag, PhD, as Senior Vice President of Software Engineering.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2020 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for d